论文信息 - International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation - 字舞流文

International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation

M. King | W. Foulkes | C. Lázaro | D. Yannoukakos | S. Casadei | E. Friedman | R. Lidereau | G. Giannini | A. Amorim | S. Narod | A. Gulino | C. Alonso | T. Ramón Y Cajal | O. Díez | S. Gutiérrez‐Enríquez | E. Velasco | L. Sunde | Y. Bignon | M. Baiget | A. Gerdes | P. Ashton-Prolla | L. Gusmão | D. Carraro | M. Thomassen | M. Teixeira | J. Balmaña | M. Tischkowitz | N. Sabbaghian | L. Feliubadaló | E. Teugels | T. Kruse | I. Blanco | T. Caldés | E. Rouleau | Y. Laitman | M. Durán | B. Paillerets | A. Vega | R. Royer | N. Uhrhammer | A. Remenieras | M. Achatz | A. Peixoto | L. Mota-Vieira | P. Maillet | A. Hout | M. J. Soares | D. Cruger | T. Rajkumar | M. Pinheiro | B. Graña | Miguel de la Hoya | M. Costa | P. Pinto | Catarina Santos | P. Rocha | C. Benson | M. Pertesi | A. Blanco | G. Benais-Pont | M. Miramar | M. Calvo | I. Ewald | R. Kyle | B. Pardo | A. R. Valle | L. Cornil | Ana Peixoto

[1] M. King,et al. Genetic Heterogeneity in Human Disease , 2010, Cell.

[2] M. Teixeira,et al. Molecular diagnosis of the Portuguese founder mutation BRCA2 c.156_157insAlu , 2009, Breast Cancer Research and Treatment.

[3] A. Amorim,et al. The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal , 2009, Breast Cancer Research and Treatment.

[4] D. Pereira,et al. Haplotype and quantitative transcript analyses of Portuguese breast/ovarian cancer families with the BRCA1 R71G founder mutation of Galician origin , 2009, Familial Cancer.

[5] Thomas D. Schmittgen,et al. Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[6] Olufunmilayo I. Olopade,et al. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations , 2007, Nature Reviews Cancer.

[7] C. Alonso,et al. Caution should be used when interpreting alterations affecting the exon 3 of the BRCA2 gene in breast/ovarian cancer families. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8] S. Tsuji,et al. Asian origin for the worldwide-spread mutational event in Machado-Joseph disease. , 2007, Archives of neurology.

[9] Á. Carracedo,et al. Multiplex SNaPshot for detection of BRCA1/2 common mutations in Spanish and Spanish related breast/ovarian cancer families , 2007, BMC Medical Genetics.

[10] S. Cascio,et al. Founder mutations in BRCA1 and BRCA2 genes. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[11] R. Brandão,et al. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12] D. Pereira,et al. BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families , 2006, Familial Cancer.

[13] W. Lissens,et al. De novo Alu element insertions targeted to a sequence common to the BRCA1 and BRCA2 genes , 2005, Human mutation.

[14] B Rannala,et al. Using linked markers to infer the age of a mutation , 2001, Human mutation.

[15] J Chang-Claude,et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[16] Cécile Fizames,et al. The 1993–94 Généthon human genetic linkage map , 1994, Nature Genetics.